Endothelium-dependent coronary vasodilatation requires NADPH oxidase-derived reactive oxygen species

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 9, 2010, Pages 1703-1710

  Feng, Jun ^a   Damrauer, Scott M ^b,c,d   Lee, Monica ^a   Sellke, Frank W ^a   Ferran, Christiane ^d   Abid, Md Ruhul ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b BROWN UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

coronary artery disease; endothelial function; NADPH oxidase; nitric oxide; reactive oxygen species; signal transduction

Indexed keywords

CITRULLINE; DICHLOROFLUORESCEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; LUCIGENIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P47; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; VASCULOTROPIN; NEUTROPHIL CYTOSOLIC FACTOR 1; NITRIC OXIDE; NOS3 PROTEIN, MOUSE; SCAVENGER; VASCULOTROPIN A; VASODILATOR AGENT;

ADENOVIRUS; ANIMAL CELL; ARTICLE; BIOAVAILABILITY; BLOOD VESSEL TONE; CORONARY BLOOD VESSEL; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FLUORESCENCE ACTIVATED CELL SORTING; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; VASCULAR ENDOTHELIUM; VASODILATATION; WESTERN BLOTTING; WILD TYPE; ADENOVIRIDAE; ANIMAL; C57BL MOUSE; DEFICIENCY; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; KNOCKOUT MOUSE; METABOLISM; PHOSPHORYLATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOVIRIDAE; ANIMALS; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; FREE RADICAL SCAVENGERS; GENETIC VECTORS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NADPH OXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; TRANSDUCTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASODILATION; VASODILATOR AGENTS; PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 77955983244     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.209726     Document Type: Article

References (64)

1. Ray R, Shah AM. NADPH oxidase and endothelial cell function. Clin Sci (Lond). 2005;109:217-226.
2. Fichtlscherer S, Dimmeler S, Breuer S, Busse R, Zeiher AM, Fleming I. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease. Circulation. 2004;109:178-183.
3. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KR, Quyyumi AA. Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002;106:653-658.
4. Irani K. Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res. 2000;87: 179-183.
5. Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res. 1999;85:753-766.
6. Patterson C, Ruef J, Madamanchi NR, Barry-Lane P, Hu Z, Horaist C, Ballinger CA, Brasier AR, Bode C, Runge MS. Stimulation of a vascular smooth muscle cell NAD(P)H oxidase by thrombin: evidence that p47(phox) may participate in forming this oxidase in vitro and in vivo. J Biol Chem. 1999;274:19814- 19822.
7. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angioten-sin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141-1148.
8. Marumo T, Schini-Kerth VB, Fisslthaler B, Busse R. Platelet-derived growth factor-stimulated superoxide anion production modulates activation of transcription factor NF-kappaB and expression of monocyte chemoattractant protein 1 in human aortic smooth muscle cells. Circulation. 1997;96: 2361-2367.
9. Baas AS, Berk BC. Differential activation of mitogen-activated protein kinases by H2O2 and O2-in vascular smooth muscle cells. Circ Res. 1995;77:29-36.
10. Ushio-Fukai M, Alexander RW, Akers M, Griendling KK. p38 Mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II: role in vascular smooth muscle cell hypertrophy. J Biol Chem. 1998;273:15022-15029.
11. Ushio-Fukai M, Alexander RW, Akers M, Yin Q, Fujio Y, Walsh K, Griendling KK. Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells. J Biol Chem. 1999;274:22699-22704.
12. Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, Griendling KK. p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem. 1996;271: 23317-23321.
13. Zafari AM, Ushio-Fukai M, Akers M, Yin Q, Shah A, Harrison DG, Taylor WR, Griendling KK. Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy. Hypertension. 1998;32:488-495.
14. Abid MR, Kachra Z, Spokes KC, Aird WC. NADPH oxidase activity is required for endothelial cell proliferation and migration. FEBS Lett. 2000;486:252-256.
15. Abid MR, Tsai JC, Spokes KC, Deshpande SS, Irani K, Aird WC. Vascular endothelial growth factor induces manganese-superoxide dis-mutase expression in endothelial cells by a Rac1-regulated NADPH oxidase-dependent mechanism. FASEB J. 2001;15:2548-2550.
16. Colavitti R, Pani G, Bedogni B, Anzevino R, Borrello S, Waltenberger J, Galeotti T. Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR. J Biol Chem. 2002;277:3101-3108.
17. Ushio-Fukai M, Tang Y, Fukai T, Dikalov SI, Ma Y, Fujimoto M, Quinn MT, Pagano PJ, Johnson C, Alexander RW. Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circ Res. 2002;91:1160-1167.
18. White CR, Brock TA, Chang LY, Crapo J, Briscoe P, Ku D, Bradley WA, Gianturco SH, Gore J, Freeman BA, Tarpey MM. Superoxide and per-oxynitrite in atherosclerosis. Proc Natl Acad Sci\USA. 1994;91: 1044-1048.
19. Davidson CA, Kaminski PM, Wolin MS. Endogenous peroxynitrite generation causes a subsequent suppression of coronary arterial contraction to serotonin. Nitric Oxide. 1997;1:244-253.
20. Pagano PJ, Griswold MC, Najibi S, Marklund SL, Cohen RA. Resistance of endothelium-dependent relaxation to elevation of O(-)(2) levels in rabbit carotid artery. Am J Physiol. 1999;277:H2109-H2114.
21. Wattanapitayakul SK, Weinstein DM, Holycross BJ, Bauer JA. Endothe-lial dysfunction and peroxynitrite formation are early events in angioten-sin-induced cardiovascular disorders. FASEB J. 2000;14:271-278.
22. Laursen JB, Somers M, Kurz S, McCann L, Warnholtz A, Freeman BA, Tarpey M, Fukai T, Harrison DG. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between per-oxynitrite and tetrahydrobiopterin. Circulation. 2001;103:1282-1288.
23. Schleicher M, Sessa WC. Are the mechanisms for NO-dependent vascular remodeling different from vasorelaxation in vivo? Arterioscler Thromb Vasc Biol. 2008;28:1207-1208.
24. Sessa WC. eNOS at a glance. J Cell Sci. 2004;117:2427-2429.
25. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, Fishman MC. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 1995;377:239-242.
26. Whalen EJ, Foster MW, Matsumoto A, Ozawa K, Violin JD, Que LG, Nelson CD, Benhar M, Keys JR, Rockman HA, Koch WJ, Daaka Y, Lefkowitz RJ, Stamler JS. Regulation of beta-adrenergic receptor signaling by S-nitrosylation of G-protein-coupled receptor kinase 2. Cell. 2007;129:511-522.
27. Stamler JS. Nitroglycerin-mediated S-nitrosylation of proteins: a field comes full cycle. Circ Res. 2008;103:557-559.
28. Lima B, Forrester MT, Hess DT, Stamler JS. S-nitrosylation in cardiovascular signaling. Circ Res. 2010;106:633-646.
29. Li JM, Shah AM. Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am J Physiol Regul Integr Comp Physiol. 2004;287:R1014-R1030.
30. Zachary I, Mathur A, Yla-Herttuala S, Martin J. Vascular protection: a novel nonangiogenic cardiovascular role for vascular endothelial growth factor. Arterioscler Thromb Vasc Biol. 2000;20:1512-1520.
31. Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol. 2001;280: C1375-C1386.
32. Pepper MS, Ferrara N, Orci L, Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun. 1991;181:902-906.
33. Blum S, Issbruker K, Willuweit A, Hehlgans S, Lucerna M, Mechtch-eriakova D, Walsh K, von Der Ahe D, Hofer E, Clauss M. An inhibitory role of the phosphatidylinositol 3-kinase-signaling pathway in vascular endothelial growth factor-induced tissue factor expression. J Biol Chem. 2001;276:33428-33434.
34. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989;246:1309-1312.
35. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983-985.
36. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperperme-ability, and angiogenesis. Am J Pathol. 1995;146:1029-1039.
37. Brown LF, Yeo KT, Berse B, Yeo TK, Senger DR, Dvorak HF, Van De Water L. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med. 1992;176:1375-1379.
38. Isner JM, Losordo DW. Therapeutic angiogenesis for heart failure. Nat Med. 1999;5:491-492.
39. Banai S, Jaklitsch MT, Shou M, Lazarous DF, Scheinowitz M, Biro S, Epstein SE, Unger EF. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation. 1994;89:2183-2189.
40. Fulton D, Fontana J, Sowa G, Gratton JP, Lin M, Li KX, Michell B, Kemp BE, Rodman D, Sessa WC. Localization of endothelial nitric-oxide synthase phosphorylated on serine 1179 and nitric oxide in Golgi and plasma membrane defines the existence of two pools of active enzyme. J Biol Chem. 2002;277:4277-4284.
41. Scotland RS, Morales-Ruiz M, Chen Y, Yu J, Rudic RD, Fulton D, Gratton JP, Sessa WC. Functional reconstitution of endothelial nitric oxide synthase reveals the importance of serine 1179 in endothelium-dependent vasomotion. Circ Res. 2002;90:904-910.
42. Miao RQ, Fontana J, Fulton D, Lin MI, Harrison KD, Sessa WC. Dominant-negative Hsp90 reduces VEGF-stimulated nitric oxide release and migration in endothelial cells. Arterioscler Thromb Vasc Biol. 2008; 28:105-111.
43. Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C, Kearney M, Chen D, Symes JF, Fishman MC, Huang PL, Isner JM. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest. 1998;101:2567-2578.
44. Tio RA, Wijpkema JS, Tan ES, Asselbergs FW, Hospers GA, Jessurun GA, Zijlstra F. Functional characteristics of coronary vasomotor function following intramyocardial gene therapy with naked DNA encoding for vascular endothelial growth factor165. Endothelium. 2005;12:103-106.
45. Chen Y, Medhora M, Falck JR, Pritchard KA Jr, Jacobs ER. Mechanisms of activation of eNOS by 20-HETE and VEGF in bovine pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2006;291: L378-L385.
46. Abid MR, Spokes KC, Shih SC, Aird WC. NADPH oxidase activity selectively modulates vascular endothelial growth factor signaling pathways. J Biol Chem. 2007;282:35373-35385.
47. Phung TL, Ziv K, Dabydeen D, Eyiah-Mensah G, Riveros M, Perruzzi C, Sun J, Monahan-Earley RA, Shiojima I, Nagy JA, Lin MI, Walsh K, Dvorak AM, Briscoe DM, Neeman M, Sessa WC, Dvorak HF, Benjamin LE. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell. 2006;10:159-170.
48. Abid MR, Schoots IG, Spokes KC, Wu SQ, Mawhinney C, Aird WC. Vascular endothelial growth factor-mediated induction of manganese superoxide dismutase occurs through redox-dependent regulation of forkhead and IkappaB/NF-kappaB. J Biol Chem. 2004;279:44030-44038.
49. Feng J, Liu Y, Clements RT, Sodha NR, Khabbaz KR, Senthilnathan V, Nishimura KK, Alper SL, Sellke FW. Calcium-activated potassium channels contribute to human coronary microvascular dysfunction after cardioplegic arrest. Circulation. 2008;118:S46-S51.
50. Boodhwani M, Nakai Y, Voisine P, Feng J, Li J, Mieno S, Ramlawi B, Bianchi C, Laham R, Sellke FW. High-dose atorvastatin improves hyper-cholesterolemic coronary endothelial dysfunction without improving the angiogenic response. Circulation. 2006;114:I402-I408.
51. Feng J, Bianchi C, Li J, Sellke FW. Bradykinin preconditioning preserves coronary microvascular reactivity during cardioplegia-reperfusion. Ann Thorac Surg. 2005;79:911-916.
52. Abid MR, Guo S, Minami T, Spokes KC, Ueki K, Skurk C, Walsh K, Aird WC. Vascular endothelial growth factor activates PI3K/Akt/forkhead signaling in endothelial cells. Arterioscler Thromb Vasc Biol. 2004;24:294-300.
53. Abid MR, Yi X, Yano K, Shih SC, Aird WC. Vascular endocan is preferentially expressed in tumor endothelium. Microvasc Res. 2006;72: 136-145.
54. Abid MR, Yano K, Guo S, Patel VI, Shrikhande G, Spokes KC, Ferran C, Aird WC. Forkhead transcription factors inhibit vascular smooth muscle cell proliferation and neointimal hyperplasia. J Biol Chem. 2005;280: 29864-29873.
55. Abid MR, Shih SC, Otu HH, Spokes KC, Okada Y, Curiel DT, Minami T, Aird WC. A novel class of vascular endothelial growth factor-responsive genes that require forkhead activity for expression. J Biol Chem. 2006;281:35544-35553.
56. Svensson EC, Marshall DJ, Woodard K, Lin H, Jiang F, Chu L, Leiden JM. Efficient and stable transduction of cardiomyocytes after intramyo-cardial injection or intracoronary perfusion with recombinant adeno-associated virus vectors. Circulation. 1999;99:201-205.
57. Ardehali A, Fyfe A, Laks H, Drinkwater DC Jr, Qiao JH, Lusis AJ. Direct gene transfer into donor hearts at the time of harvest. J Thorac Car-diovasc Surg. 1995;109:716-719; discussion, 719-720.
58. Hess CN, Kou R, Johnson RP, Li GK, Michel T. ADP signaling in vascular endothelial cells: ADP-dependent activation of the endothelial isoform of nitric-oxide synthase requires the expression but not the kinase activity of AMP-activated protein kinase. J Biol Chem. 2009;284: 32209-32224.
59. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399:601-605.
60. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999;399: 597-601.
61. Fernandez-Hernando C, Ackah E, Yu J, Suarez Y, Murata T, Iwakiri Y, Prendergast J, Miao RQ, Birnbaum MJ, Sessa WC. Loss of Akt1 leads to severe atherosclerosis and occlusive coronary artery disease. Cell Metab. 2007;6:446-457.
62. Cosentino F, Hishikawa K, Katusic ZS, Luscher TF. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation. 1997;96:25-28.
63. Zhang Q, Malik P, Pandey D, Gupta S, Jagnandan D, Belin De Chantemele E, Banfi B, Marrero MB, Rudic RD, Stepp DW, Fulton DJ. Paradoxical activation of endothelial nitric oxide synthase by NADPH oxidase. Arterioscler Thromb Vasc Biol. 2008;28:1627-1633.
64. Sawada N, Salomone S, Kim HH, Kwiatkowski DJ, Liao JK. Regulation of endothelial nitric oxide synthase and postnatal angiogenesis by Rac1. Circ Res. 2008;103:360-368.